News und Analysen
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
BASTIDE : Correctif à l'avis de réunion du 25.10.2017 (Ag 30.11.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
Rectificatif à....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
Keryx Pharmaceuticals' (NASDAQ: KERX) Auryxia just won the Food and Drug Administration (FDA) green light for boosting iron levels in non-dialysis chronic kidney disease patients, but shares....
BASTIDE : Avis de convocation à l'Assemblée Générale du 30 novembre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12, avenue de la Dame, Zone euro 2000
30132 Caissargues
305 635 039 RCS NIMES
AVIS DE....
Why Neos Therapeutics Inc Rose 13.7% In October
Shares of Neos Therapeutics (NASDAQ: NEOS), a small-cap pharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), jumped 13.7% in October according to data from S&P....
3 Unknown, but Amazing, Dividend Stocks
While most income investors focus their time studying large-cap stocks, it's worth remembering that there are scores of small-cap dividend stocks that are worthy of consideration, too. Which....
Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit....
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday's trading session following the....
Here's Why Spark Therapeutics, Inc. Fell 9.3% in October
Shares of Spark Therapeutics, Inc. (NASDAQ: ONCE), a clinical-stage biotech advancing a once-and-done gene therapy approach to treating genetic disorders, have given back some of August's gains.....
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a small-cap biotech company with a focus on a broad array of specialty disease indications, vaulted higher by 10% during the month of October,....
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from....
Here's Why Teligent Stock Was Cut Nearly in Half Today
Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company's third-quarter 2017 results. Operations appeared....
Why Celldex Therapeutics Jumped Higher Today
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is up 16% at 12:04 p.m. EST after releasing third-quarter earnings this morning, although the stock move likely has more to do with data released in....
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
Why Celldex Therapeutics Stock Crumbled in October
Shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) fell by 14.7% in October, according to S&P Global Market Intelligence. The good news -- if you can call it that -- is....
The Insurer That's Crushing It in Obamacare
Worry that Obamacare is on life support doesn't seem to scare Centene Corporation (NYSE: CNC) CEO Michael Neidorff. Over the past few years, he's been significantly increasing Centene's exposure....